Table 2.
Baseline clinical characteristics and Pretransplant Assessment of Mortality (PAM) score according to DLCO category
| Pretransplant percent of predicted DLCO category |
||||
|---|---|---|---|---|
| Characteristic | 50–60% (N=167) | 40–49% (N=40) | <40% (N=14) | P-value |
| Age (years) | 41.7 (16.1–70.7) | 40.5 (21.4–67.9) | 35.3 (15.7–54.15) | 0.677 |
| Conditioning regimen | ||||
| Nonmyeloablative | 12 (7) | 7 (17) | 5 (36) | 0.066 |
| Non-total body irradiation | 67 (40) | 13 (33) | 3 (21) | |
| Total-body irradiation with ≤12Gy | 42 (25) | 9 (22) | 3 (21) | |
| Total-body irradiation with >12Gy | 46 (28) | 11 (28) | 3 (21) | |
| Donor type | ||||
| Autologous | 49 (29) | 6 (15) | 1 (7) | 0.294 |
| Matched related | 58 (35) | 18 (45) | 7 (50) | |
| Mismatched related | 42 (25) | 12 (30) | 5 (36) | |
| Unrelated | 18 (11) | 4 (10) | 1 (7) | |
| Disease risk | ||||
| Low | 9 (5) | 2 (5) | 0 (0) | 0.384 |
| Moderate | 47 (28) | 6 (15) | 5 (36) | |
| High | 111 (66) | 32 (80) | 9 (64) | |
| Serum alanine aminotransferase (U/L) | 26.0 (6–476) | 26 (5–217) | 31 (2–100) | 0.6 |
| Serum creatinine (mg/dL) | 0.8 (0.3–5.1) | 0.85 (0.4–8.7) | 0.95 (0.4–2.4) | 0.750 |
| Percent of predicted FEV1 | 74% (39%–111%) | 66% (35%–90%) | 52% (26%–100%) | 0.06 |
| PAM score* | 30.69 (15–42) | 31.74 (15–43) | 32.0 (26–43) | 0.997 |
Numbers represent either median (range) or count (%).
*
PAM score calculated for only allogeneic transplant patients